Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user eating cotton candy with his wife.
Potential OPDIVO® (nivolumab) user eating cotton candy with his wife.

Clinical trial results for
early-stage non-small cell lung cancer (NSCLC) before and after surgery

Given before and after surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery

Actor portrayals.

An FDA-approved combination of immunotherapy and chemotherapy before surgery and immunotherapy alone after surgery that helped reduce the risk of cancer spreading or returning compared to chemotherapy alone before surgery.

This pre-surgery and post-surgery immunotherapy treatment may offer you an additional way to treat your condition. Before surgery, these treatments help shrink tumors. After surgery, they attack cancer cells that may remain “hidden” or hard to see and aim to keep them from coming back.

image treatment plan

About the clinical trial

In a clinical trial of 461 people with early-stage NSCLC who were able to have surgery, 229 people were given OPDIVO + chemotherapy before surgery followed by OPDIVO alone after surgery, and 232 people were given platinum-based chemotherapy before surgery followed by placebo after surgery.

More people given the OPDIVO-based treatment did not have their cancer return or spread compared to chemotherapy alone at a minimum follow-up of 16 months

76%  given OPDIVO® + chemo, then OPDIVO® alone didn't have their cancer spread or return, compared to 61% given placebo + chemo then placebo alone.

OPDIVO + chemotherapy and OPDIVO alone will not work for everyone. Individual results may vary.

OPDIVO Qvantig may be a faster* way to receive treatment.

It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

Timer icon indicating the injection of OPDIVO® QVANTIG™ takes 3-5 minutes.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.

Getting treatment

See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)

For adults with early-stage non-small cell lung cancer (NSCLC) before and after surgery

As an intravenous infusion

OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

As a subcutaneous injection

OPDIVO Qvantig (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early stage lung cancer (called non-small cell lung cancer) that does not have an abnormal EGFR or ALK gene and then may be continued alone after surgery to help prevent your lung cancer from coming back.

It is not known if OPDIVO Qvantig is safe and effective in children.

 



466-US-2500008  03/25